CN1321483A - Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate - Google Patents
Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate Download PDFInfo
- Publication number
- CN1321483A CN1321483A CN 00114537 CN00114537A CN1321483A CN 1321483 A CN1321483 A CN 1321483A CN 00114537 CN00114537 CN 00114537 CN 00114537 A CN00114537 A CN 00114537A CN 1321483 A CN1321483 A CN 1321483A
- Authority
- CN
- China
- Prior art keywords
- psoralen
- chinese medicine
- prostate
- hyperplasia
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 5
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 15
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001446509 Psoralea Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 3
- 230000001826 anti-prostatic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940072254 proscar Drugs 0.000 description 2
- 210000000064 prostate epithelial cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for curing hyperplasia of prostate-psoralen preparation uses the psoralen extracted from Chinese medicinal material psoralea fruit as main raw material, and possesses the advantages of low-cost, obvious therapeutic effect and quickly obtaining result. Its purity is at least 95%.
Description
The present invention is a kind of Chinese medicine of preventing and treating hyperplasia of prostate a---psoralen preparation.
Hyperplasia of prostate is a kind of common disease of elderly men.According to statistics, the survivor appears increasing in man's prostata tissue, accounts in 50 years old to account for 90% in 40%, 80 years old.Therapeutic Method is in the past based on operation, because wound is big, post-operative complication is many, thus the trend that transfers to based on Drug therapy is arranged at present, but in numerous medicines, exist the slow and expensive defective of price of onset again.
The objective of the invention is to overcome above-mentioned prior art defective, a kind of Chinese medicine of preventing and treating hyperplasia of prostate--psoralen preparation is provided, this medicine is low price not only, have no side effect, and it is rapid-action, good effect is a kind of medicinal plants of the comparatively ideal anti-prostatic hyperplasia disease that is worthy of popularization.
The object of the present invention is achieved like this: adopting the psoralen that extracts in the bone fat of therefrom building up one's health by taking tonic is major ingredient, and psoralen purity is 95% at least.
Above-mentioned psoralen has the effect that suppresses prostatic hyperplasia, and its mechanism may be to impel the prostate epithelial cell apoptosis.
The present invention has the effect of anti-prostatic hyperplasia disease, and curative effect is better than the proscar medicine, and rapid-action.
The invention will be further described below in conjunction with embodiment.
Embodiment:
The major ingredient that adopts is the middle psoralen that extracts of bone fat (meeting Pharmacopoeia of People's Republic of China nineteen ninety-five version) of therefrom building up one's health by taking tonic, its purity is 95% at least, consumption is adult dosage 10-300mg every day, and the psoralen reference substance is available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.After weighing, psoralen is ground into fine powder, crosses 40 mesh sieves, make various dosage forms after adding corresponding appropriate amount of auxiliary materials, be used to prevent and treat hyperplasia of prostate.
The dosage form of this medicine can be capsule, pill, tablet or liquid, powder, electuary etc., and its manufacture method is a common process.
The effect characteristics of psoralen anti-prostatic hyperplasia of the present invention, obtain following result by animal experiment:
1, after 30 days, prostatic weight, volume are obviously dwindled the SD rat clothes psoralen of the prostatic hyperplasia due to the androlin, prostata tissue is learned hyperplasia degree and is alleviated, and the prostate epithelial cell apoptosis rate increases.Compare with proscar, significant difference is arranged, P＜0.05.
2, plasma testosterone, estradiol there is not change.
Claims (4)
1, a kind of Chinese medicine of preventing and treating hyperplasia of prostate is characterized in that adopting with the psoralen that extracts in the Chinese medicine Fructus Psoraleae is major ingredient, and psoralen purity is 95% at least.
2, the Chinese medicine of control hyperplasia of prostate according to claim 1 is characterized in that the psoralen consumption is adult dosage 10-300mg every day.
3, the Chinese medicine of control hyperplasia of prostate according to claim 1 and 2 is characterized in that described Chinese medicine is capsule or pill or tablet, and it is mixed and made into the major ingredient psoralen fine powder of crossing 40 mesh sieves by by adding corresponding appropriate amount of auxiliary materials.
4, the Chinese medicine of control hyperplasia of prostate according to claim 1 and 2 is characterized in that described Chinese medicine is liquid or powder or electuary, and it is mixed and made into the major ingredient psoralen fine powder of crossing 40 mesh sieves by by adding corresponding appropriate amount of auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001145371A CN1150899C (en) | 2000-04-29 | 2000-04-29 | Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001145371A CN1150899C (en) | 2000-04-29 | 2000-04-29 | Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1321483A true CN1321483A (en) | 2001-11-14 |
| CN1150899C CN1150899C (en) | 2004-05-26 |
Family
ID=4584204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001145371A Expired - Fee Related CN1150899C (en) | 2000-04-29 | 2000-04-29 | Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150899C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580932A (en) * | 2016-11-30 | 2017-04-26 | 天津中医药大学 | Application of bakuchiol in preparing medicine for preventing and/or treating benign prostatic hyperplasia |
-
2000
- 2000-04-29 CN CNB001145371A patent/CN1150899C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580932A (en) * | 2016-11-30 | 2017-04-26 | 天津中医药大学 | Application of bakuchiol in preparing medicine for preventing and/or treating benign prostatic hyperplasia |
| CN106580932B (en) * | 2016-11-30 | 2019-06-07 | 天津中医药大学 | Bakuchiol is preparing the purposes in the drug for preventing and/or treating benign prostatic hyperplasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150899C (en) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abd Jalil et al. | Role of medicinal plants and natural products on osteoporotic fracture healing | |
| CN105412569A (en) | Composition for increasing bone mineral density and preparation and preparation method thereof | |
| CN100488529C (en) | Novel use of compound salvia miltiorrhiza tablet for preventing and treating osteoporosis | |
| US20060093619A1 (en) | Medicament for prevention and treatment of bone fracture and osteoporosis | |
| CN1150899C (en) | Chinese medicine-psoralen preparation for preventing and curing hyperplasia of prostate | |
| CN101485722B (en) | Rhizoma drynariae and salvia miltiorrhiza medicinal composition and application thereof | |
| WO2021179482A1 (en) | Traditional chinese medicine compound composition having effect of promoting bone health as well as preparation method therefor and application thereof | |
| CN1292272A (en) | Medicine for curing diabetes and its preparation method | |
| CN1322888C (en) | Medicine for treating osteoporosis and its preparing method and use | |
| CN101596263A (en) | A kind of medicine for the treatment of fracture and preparation method thereof | |
| CN1235029A (en) | Medicine for regulating menstruation and arresting bleeding and producing process therefor | |
| CN101579388B (en) | Medicinal composition for treating osteoporosis and preparation method thereof | |
| CN101152328A (en) | Traditional Chinese medicine for treating nasal obstruction of chronic rhinitis | |
| KR101636612B1 (en) | Composition comprising the extract of Rubus coreanus Miquel and Astragalus membranaceus Bunge for preventing and treating of osteoporosis and bone disease | |
| CN100335080C (en) | Medication for treating diabetes | |
| CN1330325C (en) | Medicine for preventing and curing osteoporosis and its preparing method | |
| CN1211118C (en) | Formula of medication for treating bone fracture and contuse | |
| CN118078837A (en) | Use of oleanolic acid in preventing osteoporosis | |
| CN101618102B (en) | Chinese medicinal preparation for treating breast diseases and preparation method thereof | |
| CN1954841B (en) | Medicine for treating chronic pharyngitis | |
| CN101732418A (en) | Chinese medicinal paste for treating diabetes | |
| CN101024029A (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN101152361A (en) | Traditional Chinese medicine for treating chronic simple rhinitis | |
| CN1836567A (en) | Health food for adjusting female physiological function | |
| CN100363049C (en) | Chinese medicine for treating prostatitis, impotence and premature ejaculation, its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |